Male Infertility - Pipeline Review H2 2017 pipeline guide provides comprehensive information on the therapeutics under development for Male Infertility (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. —
Report provides an overview of the Male Infertility (Male Health) pipeline therapeutics landscape. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Companies in Male Infertility Therapeutics Development are:
Cadila Healthcare Ltd, Ferring International Center SA, Health Ever Bio-Tech Co. Ltd, Navya Biologicals Pvt Ltd.
Inquire For this complete report with table and figures data of 36 pages at: http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=1185135
Male Infertility Pipeline Drugs Profiles:
Biosimilar 2 for Diabetes, Infertility and Rheumatoid Arthritis, Biosimilar 5 for Infertility and Oncology, Biosimilar 6 for Infertility, Oncology and Immunology, Biosimilar 7 for Infertility, Immunology, Male Health and Oncology, FE-999310, LM-002, MCS-5, NAV-013, PAM-8, PKB-171, Recombinant Beta Glucosidase 2 Replacement for Gaucher’s Disease and Male Infertility, TOP-001, TOP-002, trequinsin.
The Male Infertility (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Male Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 5, 2 and 1 respectively.
Male Infertility (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
• The pipeline guide provides a snapshot of the global therapeutic landscape of Male Infertility (Male Health).
• The pipeline guide reviews pipeline therapeutics for Male Infertility (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Male Infertility (Male Health) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Male Infertility (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Male Infertility (Male Health).
Order copy of complete report at: http://www.reportsnreports.com/purchase.aspx?name=1185135
Reasons to buy this report:
• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Male Infertility (Male Health).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Male Infertility (Male Health) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
List of Tables:
• Number of Products under Development for Male Infertility, H2 2017
• Number of Products under Development by Companies, H2 2017
• Number of Products under Development by Universities/Institutes, H2 2017
• Products under Development by Companies, H2 2017
• Products under Development by Universities/Institutes, H2 2017
• Number of Products by Stage and Target, H2 2017
• Number of Products by Stage and Mechanism of Action, H2 2017
• Number of Products by Stage and Route of Administration, H2 2017
• Number of Products by Stage and Molecule Type, H2 2017
• Male Infertility - Pipeline by Cadila Healthcare Ltd, H2 2017
• Male Infertility - Pipeline by Ferring International Center SA, H2 2017
• Male Infertility - Pipeline by Health Ever Bio-Tech Co Ltd, H2 2017
• Male Infertility - Pipeline by Navya Biologicals Pvt Ltd, H2 2017
• Male Infertility - Dormant Projects, H2 2017
ReportsnReports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Name: Hrishikesh Patwardhan
Email: Send Email
Phone: + 1 888 391 5441
Release ID: 239851